Clinical utility of indium 111‐capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy

Despite the ability of radical prostatectomy to eradicate prostate carcinoma, biochemical evidence of recurrent prostate carcinoma may be seen in approximately 40% of patients 15 years after they undergo surgery. Localization of recurrent disease after radical prostatectomy is difficult and may greatly influence subsequent clinical management. The authors examined the utility of indium 111 (111In)‐capromab pendetide immunoscintigraphy to detect recurrent prostate carcinoma radiographically in men with early biochemical evidence of failure (serum prostate specific antigen [PSA] ≤ 4.0 ng/mL) and assessed the minimum serum PSA level necessary for imaging recurrent disease.

[1]  R. S. Anderson,et al.  Radioimmunoguided surgery using indium-111 capromab pendetide (PROSTASCINT) to diagnose supraclavicular metastasis from prostate cancer. , 2000, Urology.

[2]  A. Belldegrun,et al.  Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer. , 1999, The Journal of urology.

[3]  A W Partin,et al.  Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. , 1993, The Urologic clinics of North America.

[4]  R. Bahnson,et al.  Preliminary imaging results using In-111 labeled CYT-356 (Prostascint) in the detection of recurrent prostate cancer. , 1996, Clinical nuclear medicine.

[5]  F. Vicini,et al.  Treatment outcome with adjuvant and salvage irradiation after radical prostatectomy for prostate cancer. , 1999, Urology.

[6]  M. Banerjee,et al.  Limited role of radionuclide bone scintigraphy in patients with prostate specific antigen elevations after radical prostatectomy. , 1998, The Journal of urology.

[7]  M. Brawer,et al.  Evaluation of prostate cancer patients receiving multiple staging tests, including ProstaScint® scintiscans , 2000, The Prostate.

[8]  G H Hinkle,et al.  Multicenter radioimmunoscintigraphic evaluation of patients with prostate carcinoma using indium‐111 capromab pendetide , 1998, Cancer.

[9]  R. Maguire,et al.  Immunoscintigraphy in patients with colorectal, ovarian, and prostate cancer. Results with site‐specific immunoconjugates , 1993 .

[10]  P. Nieh,et al.  Radiolabeled monoclonal antibody indium 111-labeled CYT-356 localizes extraprostatic recurrent carcinoma after prostatectomy. , 1998, Urology.

[11]  B. Rogers,et al.  Prostate cancer abdominal metastases detected with indium-111 capromab pendetide. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[12]  A. Partin,et al.  Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. , 1994, Urology.

[13]  M. Manyak,et al.  The role of computerized tomography, magnetic resonance imaging, bone scan, and monoclonal antibody nuclear scan for prognosis prediction in prostate cancer. , 1998, Seminars in urologic oncology.

[14]  M S Anscher,et al.  Radiotherapy for a rising prostate-specific antigen after radical prostatectomy: the first 10 years. , 2000, International journal of radiation oncology, biology, physics.

[15]  Manyak.  Clinical Applications of Radioimmunoscintigraphy With Prostate-Specific Antibodies for Prostate Cancer. , 1998, Cancer control : journal of the Moffitt Cancer Center.

[16]  A W Partin,et al.  Natural history of progression after PSA elevation following radical prostatectomy. , 1999, JAMA.

[17]  A. Aschoff,et al.  Sensitivity of computed tomography in detecting local recurrence of prostatic carcinoma following radical prostatectomy. , 1997, The British journal of radiology.

[18]  Monoclonal antibody imaging of recurrent and metastatic prostate cancer. , 1995, Seminars in urology.

[19]  A W Partin,et al.  Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. , 1997, JAMA.

[20]  Manyak Mj,et al.  The role of computerized tomography, magnetic resonance imaging, bone scan, and monoclonal antibody nuclear scan for prognosis prediction in prostate cancer. , 1998 .

[21]  D. Faulds,et al.  Capromab Pendetide , 1998, Drugs & aging.

[22]  A. Partin,et al.  Comparison of serum PSMA, PSA levels with results of cytogen‐356 ProstaScint® scanning in prostatic cancer patients , 1997, The Prostate.

[23]  P. Schellhammer,et al.  Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. , 1995, Urologic oncology.

[24]  J. Cadeddu,et al.  Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy. , 1998, The Journal of urology.

[25]  M. Manyak,et al.  (111) INDIUM-CAPROMAB PENDETIDE IN THE EVALUATION OF PATIENTS WITH RESIDUAL OR RECURRENT PROSTATE CANCER AFTER RADICAL PROSTATECTOMY , 1998 .

[26]  J. McCall,et al.  Utilization of polymerase chain reaction technology in the detection of solid tumors , 1999, Cancer.

[27]  N. Bander,et al.  Capromab Pendetide A Review of its Use as an Imaging Agent in Prostate Cancer , 1998 .

[28]  G H Hinkle,et al.  Immunoscintigraphy with indium-111-capromab pendetide: evaluation before definitive therapy in patients with prostate cancer. , 1999, Urology.

[29]  G. Bakale,et al.  Multicenter ProstaScint imaging findings in 2154 patients with prostate cancer. The ProstaScint Imaging Centers. , 2000, Urology.

[30]  J. Oesterling,et al.  Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. , 1991, The Journal of urology.

[31]  Richard D. Williams,et al.  Radioimmunoscintigraphy with In-111-labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  S. Rosenthal,et al.  Monoclonal antibody imaging of occult prostate cancer in patients with elevated prostate-specific antigen. Positron emission tomography and biopsy correlation. , 1996, Clinical nuclear medicine.

[33]  C W Piccoli,et al.  Staging of prostate cancer: results of Radiology Diagnostic Oncology Group project comparison of three MR imaging techniques. , 1994, Radiology.

[34]  Burgers Jk,et al.  Monoclonal antibody imaging of recurrent and metastatic prostate cancer. , 1995 .

[35]  A. Partin,et al.  Comparison of clinical staging algorithms and 111Indium‐capromab pendetide immunoscintigraphy in the prediction of lymph node involvement in high risk prostate carcinoma patients , 1999, Cancer.

[36]  G. Kenny,et al.  Follow‐up ProstaScint® scans verify detection of occult soft‐tissue recurrence after failure of primary prostate cancer therapy , 2000, The Prostate.

[37]  S Beddar,et al.  Radioimmunoguided imaging of prostate cancer foci with histopathological correlation. , 2001, International journal of radiation oncology, biology, physics.

[38]  D. B. Sodee,et al.  Prostate cancer and prostate bed SPECT imaging with ProstaScint®: Semiquantitative correlation with prostatic biopsy results , 1998, The Prostate.

[39]  T. Polascik,et al.  Capromab Pendetide imaging of prostate cancer. , 2000, Cancer biotherapy & radiopharmaceuticals.

[40]  T. J. Robnett,et al.  PSA based review of adjuvant and salvage radiation therapy vs. observation in postoperative prostate cancer patients , 2000, International journal of cancer.

[41]  J. Oesterling,et al.  Prostate specific antigen: a decade of discovery--what we have learned and where we are going. , 1999, The Journal of urology.

[42]  M. Weston,et al.  The changing face of emphysematous cholecystitis. , 1997, The British journal of radiology.

[43]  R. Dreicer,et al.  Radioimmunoscintigraphy with 111indium labeled CYT-356 for the detection of occult prostate cancer recurrence. , 1994, The Journal of urology.

[44]  A. Partin,et al.  Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. , 1997, The Urologic clinics of North America.

[45]  J. Moul.  Prostate specific antigen only progression of prostate cancer. , 2000, The Journal of urology.

[46]  J. Obrecht.  [Cancer therapy]. , 1977, Deutsche medizinische Wochenschrift.

[47]  F Regan,et al.  Indium-111 capromab pendetide (ProstaScint) imaging to detect recurrent and metastatic prostate cancer. , 1998, Clinical nuclear medicine.

[48]  G. Murphy,et al.  ProstaScint® scan may enhance identification of prostate cancer recurrences after prostatectomy, radiation, or hormone therapy: Analysis of 136 scans of 100 patients , 1998 .